DNA · Insider Trading
Ginkgo Bioworks Holdings, Inc.
Every open-market purchase and sale reported by DNA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Reshma P. Shetty | See remarks | MIXED | +35,290 | −$417.61K |
| 2026-10-21 | Jason R Kelly | See remarks | MIXED | +35,802 | −$463.35K |
| 2026-10-21 | Steven P. Coen | See remarks | MIXED | +720 | −$7.77K |
| 2026-10-21 | Barry Canton | 10%+ Owner | MIXED | +35,290 | −$417.61K |
| 2026-10-07 | Steven P. Coen | See remarks | Sell | −2,403 | −$36.05K |
| 2026-09-16 | Christian O Henry | Director | Sell | −5,000 | −$35.41K |
| 2026-08-25 | Steven P. Coen | See remarks | MIXED | +413 | −$2.30K |
| 2026-07-30 | Reshma P. Shetty | See remarks | A | +319,332 deriv. | — |
| 2026-07-30 | Barry Canton | 10%+ Owner | A | +319,332 deriv. | — |
| 2026-07-30 | Jason R Kelly | See remarks | A | +383,725 deriv. | — |
| 2026-07-20 | Steven P. Coen | See remarks | MIXED | +734 | −$5.94K |
| 2026-06-15 | Sri Kosuri | Director | A | +25,000 deriv. | — |
| 2026-06-15 | Harry Sloan | Director | A | +25,000 deriv. | — |
| 2026-06-15 | Christian O Henry | Director | A | +25,000 deriv. | — |
| 2026-06-15 | Ross Fubini | Director | A | +25,000 deriv. | — |
| 2026-05-26 | Steven P. Coen | See remarks | MIXED | +436 | −$2.56K |
| 2026-04-20 | Steven P. Coen | See remarks | MIXED | +419 | −$2.58K |
| 2026-04-14 | Steven P. Coen | See remarks | MIXED | +40,750 | −$212.76K |
| 2026-04-13 | Barry Canton | 10%+ Owner | MIXED | +127,059 | −$802.49K |
| 2026-04-13 | Reshma P. Shetty | See remarks | MIXED | +127,059 | −$802.49K |
| 2026-04-10 | Reshma P. Shetty | See remarks | MIXED | +29,205 | −$175.07K |
| 2026-04-10 | Barry Canton | 10%+ Owner | MIXED | +29,205 | −$175.07K |
| 2026-04-10 | Jason R Kelly | See remarks | MIXED | +219,116 | −$1.37M |
| 2026-03-18 | Steven P. Coen | See remarks | MIXED | +778 | −$4.77K |
| 2026-01-22 | Steven P. Coen | See remarks | MIXED | +833 | −$8.67K |
| 2025-12-16 | Steven P. Coen | See remarks | MIXED | +750 | −$6.54K |
| 2025-10-21 | Steven P. Coen | See remarks | MIXED | +1,235 | −$17.91K |
| 2025-10-03 | Steven P. Coen | See remarks | Sell | −5,609 | −$84.14K |
| 2025-09-10 | Christian O Henry | Director | Sell | −20,000 | −$219.80K |
| 2025-08-26 | Steven P. Coen | See remarks | MIXED | +433 | −$3.84K |
| 2025-07-21 | Steven P. Coen | See remarks | MIXED | +1,463 | −$10.67K |
| 2025-06-13 | Shyam Sankar | Director | M | +10,822 | — |
| 2025-06-13 | Kathy Hopinkah Hannan | Director | M | +10,822 | — |
| 2025-06-13 | Sri Kosuri | Director | M | +24,067 | — |
| 2025-06-13 | Harry Sloan | Director | M | +10,822 | — |
| 2025-06-13 | Christian O Henry | Director | M | +10,822 | — |
| 2025-06-13 | Myrtle S Potter | Director | M | +10,822 | — |
| 2025-06-13 | Ross Fubini | Director | M | +10,822 | — |
| 2025-05-22 | Mark E. Dmytruk | See remarks | MIXED | +773 | −$5.36K |
| 2025-05-22 | Steven P. Coen | See remarks | MIXED | +397 | −$2.62K |
| 2025-04-23 | Mark E. Dmytruk | See remarks | MIXED | +1,304 | −$9.06K |
| 2025-04-23 | Steven P. Coen | See remarks | MIXED | +807 | −$7.26K |
| 2025-03-17 | Mark E. Dmytruk | See remarks | C | +9,497 | — |
| 2025-03-10 | Mark E. Dmytruk | See remarks | A | +4,245 deriv. | — |
| 2025-03-10 | Steven P. Coen | See remarks | A | +4,245 deriv. | — |
| 2025-03-06 | Mark E. Dmytruk | See remarks | MIXED | +689 | −$6.10K |
| 2025-03-06 | Steven P. Coen | See remarks | MIXED | +348 | −$3.05K |
| 2025-02-06 | Mark E. Dmytruk | See remarks | MIXED | +747 | −$9.95K |
| 2025-02-06 | Steven P. Coen | See remarks | MIXED | +376 | −$4.93K |
| 2025-01-08 | Steven P. Coen | See remarks | MIXED | +419 | −$3.80K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Reshma P. Shetty | See remarks | 898,250 | $8.82M |
| Barry Canton | 10%+ Owner | 801,261 | $7.86M |
| Jason R Kelly | See remarks | 310,316 | $3.05M |
| Harry Sloan | Director | 271,418 | $2.66M |
| Shyam Sankar | Director | 72,372 | $710.33K |
| Steven P. Coen | See remarks | 49,448 | $485.33K |
| Mark E. Dmytruk | See remarks | 46,226 | $453.71K |
| Sri Kosuri | Director | 24,067 | $236.22K |
| Christian O Henry | Director | 19,310 | $189.53K |
| Kathy Hopinkah Hannan | Director | 15,003 | $147.25K |
| Myrtle S Potter | Director | 10,822 | $106.22K |
| Ross Fubini | Director | 10,822 | $106.22K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DNA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.